Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANGIODYNAMICS INC Director's Dealing 2021

Oct 21, 2021

32939_dirs_2021-10-21_0e1bcf6d-5197-48e7-9a49-2cfa905792d5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2021-07-21

Reporting Person: Piccinini Laura (SVP International)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-07-21 Common Stock A 2952 Acquired 2952 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-07-21 Performance Right $ A 5903 Acquired Common Stock (5903) Direct
2021-07-21 Non-Qualified Stock Option (right to buy) $26.49 A 8019 Acquired 2031-07-21 Common Stock (8019) Direct

Footnotes

F1: The restricted stock units, performance rights and stock options set forth in this Form 4 were granted to the Reporting Person effective July 21, 2021. Due to an administrative error, the acquisition of the securities by the Reporting Person was delayed.

F2: The acquisition of 2,952 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 2,952 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

F3: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F4: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.